India, Sept. 18 -- Jagsonpal has been reshaping its prescription business, moving away from high-volume, lower-margin acute therapies towards semi-chronic and specialty treatments. Management said the average monthly sales run-rate of new brands in these categories has almost doubled, while a more focused approach to brand building and medical-representative productivity is improving the quality of growth.

Jagsonpal Pharmaceuticals was trading at around Rs231 per share, with a market capitalization of roughly Rs1,517 crore. The stock's current P/E is around 32x, while its 5-year median P/E stands at 36.1x. This leaves the stock below its historical valuation benchmark despite the sharp recent rally. The stock has gained roughly 70% in t...